These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32761064)

  • 1. Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder.
    Schneeberger PE; Kortüm F; Korenke GC; Alawi M; Santer R; Woidy M; Buhas D; Fox S; Juusola J; Alfadhel M; Webb BD; Coci EG; Abou Jamra R; Siekmeyer M; Biskup S; Heller C; Maier EM; Javaher-Haghighi P; Bedeschi MF; Ajmone PF; Iascone M; Peeters H; Ballon K; Jaeken J; Rodríguez Alonso A; Palomares-Bralo M; Santos-Simarro F; Meuwissen MEC; Beysen D; Kooy RF; Houlden H; Murphy D; Doosti M; Karimiani EG; Mojarrad M; Maroofian R; Noskova L; Kmoch S; Honzik T; Cope H; Sanchez-Valle A; ; Gelb BD; Kurth I; Hempel M; Kutsche K
    Brain; 2020 Aug; 143(8):2437-2453. PubMed ID: 32761064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calloso-adreno-scrotal agenesis associated with biallelic MAPK-activating death domain protein (MADD) variant: Further phenotypic delineation of MADD deficiency.
    Darouich S; Darouich S
    Am J Med Genet A; 2024 Mar; 194(3):e63463. PubMed ID: 37932938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-181 interacts with signaling adaptor molecule DENN/MADD and enhances TNF-induced cell death.
    Ghorbani S; Talebi F; Ghasemi S; Jahanbazi Jahan Abad A; Vojgani M; Noorbakhsh F
    PLoS One; 2017; 12(3):e0174368. PubMed ID: 28323882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment.
    Kurada BRVVSN; Li LC; Mulherkar N; Subramanian M; Prasad KV; Prabhakar BS
    J Biol Chem; 2009 May; 284(20):13533-13541. PubMed ID: 19289468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons.
    Del Villar K; Miller CA
    Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4210-5. PubMed ID: 15007167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, biochemical, and genetic spectrum of MADD in a South African cohort: an ICGNMD study.
    Bisschoff M; Smuts I; Dercksen M; Schoonen M; Vorster BC; van der Watt G; Spencer C; Naidu K; Henning F; Meldau S; McFarland R; Taylor RW; Patel K; Fassad MR; Vandrovcova J; ; Wanders RJA; van der Westhuizen FH
    Orphanet J Rare Dis; 2024 Jan; 19(1):15. PubMed ID: 38221620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous variant in MADD, encoding a Rab guanine nucleotide exchange factor, results in pleiotropic effects and a multisystemic disorder.
    Abu-Libdeh B; Mor-Shaked H; Atawna AA; Gillis D; Halstuk O; Shaul-Lotan N; Slae M; Sultan M; Meiner V; Elpeleg O; Harel T
    Eur J Hum Genet; 2021 Jun; 29(6):977-987. PubMed ID: 33723354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3.
    Al-Zoubi AM; Efimova EV; Kaithamana S; Martinez O; El-Idrissi Mel-A; Dogan RE; Prabhakar BS
    J Biol Chem; 2001 Dec; 276(50):47202-11. PubMed ID: 11577081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual role of DENN/MADD (Rab3GEP) in neurotransmission and neuroprotection.
    Miyoshi J; Takai Y
    Trends Mol Med; 2004 Oct; 10(10):476-80. PubMed ID: 15464446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MADD/DENN/Rab3GEP functions as a guanine nucleotide exchange factor for Rab27 during granule exocytosis of rat parotid acinar cells.
    Imai A; Ishida M; Fukuda M; Nashida T; Shimomura H
    Arch Biochem Biophys; 2013 Aug; 536(1):31-7. PubMed ID: 23702376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MADD is a downstream target of PTEN in triggering apoptosis.
    Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS
    J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells.
    Murakami-Mori K; Mori S; Bonavida B; Nakamura S
    J Immunol; 1999 Mar; 162(6):3672-9. PubMed ID: 10092829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.
    Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS
    Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A splice site variant in MADD affects hormone expression in pancreatic β cells and pituitary gonadotropes.
    Pulli K; Saarimäki-Vire J; Ahonen P; Liu X; Ibrahim H; Chandra V; Santambrogio A; Wang Y; Vaaralahti K; Iivonen AP; Känsäkoski J; Tommiska J; Kemkem Y; Varjosalo M; Vuoristo S; Andoniadou CL; Otonkoski T; Raivio T
    JCI Insight; 2024 May; 9(10):. PubMed ID: 38775154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
    Turner A; Li LC; Pilli T; Qian L; Wiley EL; Setty S; Christov K; Ganesh L; Maker AV; Li P; Kanteti P; Das Gupta TK; Prabhakar BS
    PLoS One; 2013; 8(2):e56817. PubMed ID: 23457619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
    Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase.
    Schievella AR; Chen JH; Graham JR; Lin LL
    J Biol Chem; 1997 May; 272(18):12069-75. PubMed ID: 9115275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GDP/GTP exchange factor MADD drives activation and recruitment of secretory Rab GTPases to Weibel-Palade bodies.
    Kat M; Bürgisser PE; Janssen H; De Cuyper IM; Conte IL; Hume AN; Carter T; Voorberg J; Margadant C; Bierings R
    Blood Adv; 2021 Dec; 5(23):5116-5127. PubMed ID: 34551092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells.
    Mulherkar N; Prasad KV; Prabhakar BS
    J Biol Chem; 2007 Apr; 282(16):11715-21. PubMed ID: 17314102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4.
    Li P; Jayarama S; Ganesh L; Mordi D; Carr R; Kanteti P; Hay N; Prabhakar BS
    J Biol Chem; 2010 Jul; 285(29):22713-22. PubMed ID: 20484047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.